Precision Diagnostics · us
One Swab Distinguishes Two Common Types of Vaginitis: Roche Molecular Test Receives FDA Clearance
cobas BV/CV uses real-time PCR to detect microorganisms associated with bacterial vaginosis and vulvovaginal candidiasis from the same vaginal swab and allows self-collection under the guidance of a healthcare professional. The new tool may simplify laboratory workflows, but results must still be interpreted alongside symptoms.
Vaginal itching, burning, or abnormal discharge may stem from different microbial imbalances and are often difficult to distinguish based on symptoms alone. The U.S. Food and Drug Administration (FDA) recently cleared Roche’s cobas BV/CV molecular test, enabling laboratories to use a single vaginal swab to simultaneously determine whether DNA signals associated with bacterial vaginosis or vulvovaginal candidiasis are present.
This automated qualitative test uses real-time polymerase chain reaction (PCR) and is intended for people with symptoms of vaginitis or vaginal flora imbalance. Samples may be collected by a healthcare professional or self-collected under the guidance of a healthcare professional, then placed in the designated PCR preservation solution and sent for testing. It is not a self-test that can be performed independently at home with immediate results.
For bacterial vaginosis, the test analyzes relevant DNA targets including Gardnerella vaginalis, Atopobium vaginae, and several Lactobacillus species. For Candida, it covers six species, including Candida albicans, Candida glabrata, and Candida tropicalis. The system separately reports positive or negative signals associated with the two conditions but does not identify which species is present, so it cannot replace subsequent species identification or a complete clinical evaluation.
Clinical studies described in Roche’s instructions for use showed that, for bacterial vaginosis testing, sensitivity was 95.9% and specificity was 93.8% with healthcare professional-collected samples; with guided self-collection, they were 96.8% and 92.8%, respectively. For vulvovaginal candidiasis, when compared with a composite reference standard comprising three nucleic acid tests, sensitivity for the two collection methods was 93.0% and 94.5%, respectively, while specificity was 97.8% and 92.8%. These figures come from specific study populations and cannot be directly regarded as performance across all clinical settings.
The test can run on the cobas 5800 and 6800/8800 systems. Documentation states that the first results can be obtained within 3.5 hours, and cross-platform studies showed comparable clinical performance. For laboratories that already have these automated systems installed, the new reagents can incorporate two common causes into existing high-throughput workflows, reducing the burden of separate sample collection and arranging multiple tests.
FDA data show that Roche submitted a traditional 510(k) application on January 5, 2026, and the agency issued a “substantially equivalent” decision on July 16, classifying the product as a nucleic acid detection system for vaginitis and bacterial vaginosis. Clearance does not mean that a single positive result is sufficient for diagnosis: the relevant species may also be present in normal vaginal flora, and a negative result cannot rule out other causes such as Trichomonas. In particular, some non-albicans Candida species may involve resistance to antifungal drugs, so further identification may still be necessary.